Codex_V5

Jahn G

References:

Rank: 3 - Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes.(Nov 2000)
Rank: 3 - Antiviral Drug- and Multidrug Resistance in Cytomegalovirus Infected SCT Patients.( 2015)
Rank: 3 - Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation.(Dec 2013)
Rank: 5 - Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance.(Jul 2016)

Mutations:

Mutant	Gene	Virus	Reference
A492D	UL54	Human betaherpesvirus 5	Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
A492D	UL54	Human betaherpesvirus 5	Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
A492D	UL54	Human betaherpesvirus 5	Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
D515E	UL54	Human betaherpesvirus 5	Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. (Nov 2000)
D515E	UL54	Human betaherpesvirus 5	Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. (Nov 2000)
D515E	UL54	Human betaherpesvirus 5	Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. (Nov 2000)
L516W	UL54	Human betaherpesvirus 5	Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
L516W	UL54	Human betaherpesvirus 5	Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
L516W	UL54	Human betaherpesvirus 5	Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
V715A	UL54	Human betaherpesvirus 5	Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
V715A	UL54	Human betaherpesvirus 5	Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
V715A	UL54	Human betaherpesvirus 5	Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
A591V	UL97	Human betaherpesvirus 5	Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. (Nov 2000)
E596Y	UL97	Human betaherpesvirus 5	Antiviral Drug- and Multidrug Resistance in Cytomegalovirus Infected SCT Patients. ( 2015)
I610T	UL97	Human betaherpesvirus 5	Antiviral Drug- and Multidrug Resistance in Cytomegalovirus Infected SCT Patients. ( 2015)
A613V	UL97	Human betaherpesvirus 5	Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation. (Dec 2013)

CHARMD

Comprehensive Herpesviruses Antiviral drug Resistance Mutation Database

Jahn G

Mutations: